Pfizer spin-out SpringWorks Therapeutics has its first approved product after getting a green light from the FDA for Ogsiveo, the first-ever therapy for a rare type of non-cancerous tumour that can ...

Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in ...

FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...

Milestone follows disclosure of compelling preliminary data presented at the ESMO Congress and the CTOS 2025 Annual Meeting showing clinically meaningful anti-tumor activity in desmoid tumors ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Desmoid tumors are malignant non-inflammatory fibroblastic tumors with a tendency for local invasion and recurrence post resection. They are considered a locally aggressive proliferative disease ...

ABSTRACT: Desmoid tumors are malignant non-inflammatory fibroblastic tumors with a tendency for local invasion and recurrence post resection. They are considered a locally aggressive proliferative ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for desmoid tumours in Europe. Oral gamma secretase inhibitor Ogsiveo ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Merck’s therapy becomes first authorised option for aggressive soft tissue tumours Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo (nirogacestat) as ...